Trials / Withdrawn
WithdrawnNCT04712006
A Study of JNJ-64304500 Following Subcutaneous Injection in Healthy Chinese Adult Participants
Phase 1, Open-label, Single Dose Study to Investigate the Pharmacokinetics, Safety, and Tolerability of JNJ-64304500 Following Subcutaneous Injection in Healthy Chinese Adult Participants
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the pharmacokinetic following single subcutaneous administration of Dose 1 or Dose 2 of JNJ-64304500 in healthy Chinese adult participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-64304500 | Participants will be administered with JNJ-64304500 SC (Dose 1 or 2) injection on Day 1. |
Timeline
- Start date
- 2021-05-30
- Primary completion
- 2021-08-27
- Completion
- 2021-10-30
- First posted
- 2021-01-15
- Last updated
- 2021-09-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04712006. Inclusion in this directory is not an endorsement.